The Drug Controller General of India has approved the Tata CRISPR test, for its commercial launch, meeting high-quality benchmark with 96% sensitivity and 98% specificity for detecting novel coronavirus.
from Medindia Health News https://ift.tt/3ksrPP4
No comments:
Post a Comment